Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NOTCH1 | P46531 | 10/20 | 0.40 |
| ▸ | RBPJ | Q06330 | 4/20 | 0.40 |
| ▸ | NOTCH3 | Q9UM47 | 6/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 7/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 7/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 7/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 7/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 7/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 7/20 | 0.36 |
| ▸ | CCKAR | P32238 | 1/20 | 0.35 |
| ▸ | CCKBR | P32239 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6798648 | 0.83 | PSEN1 (0.51) | KMT2ANOTCH1NOTCH3PSEN1PSEN2 | |
| SCHEMBL6801316 | 0.83 | PSEN1 (0.51) | KMT2ANOTCH1NOTCH3PSEN1PSEN2 | |
| SCHEMBL6986032 | 0.80 | NOTCH1 (0.39) | NOTCH1RBPJNOTCH3PSEN1PSEN2 | |
| SCHEMBL6955893 | 0.77 | PSEN1 (0.47) | NOTCH1RBPJNOTCH3PSEN1PSEN2 | |
| SCHEMBL6805380 | 0.73 | PSEN1 (0.49) | NOTCH1RBPJNOTCH3PSEN1PSEN2 | |
| SCHEMBL6955221 | 0.67 | NOTCH1 (0.49) | NOTCH1RBPJNOTCH3PSEN1PSEN2 | |
| SCHEMBL6950859 | 0.63 | NOTCH1 (0.46) | NOTCH1RBPJNOTCH3PSEN1PSEN2 | |
| SCHEMBL16777947 | 0.62 | NOTCH1 (0.49) | KMT2ANOTCH1RBPJNOTCH3CCKAR | |
| SCHEMBL3600092 | 0.61 | PSEN1 (0.50) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL3593240 | 0.61 | PSEN1 (0.66) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6713476-B2 | SUBSTITUTED LACTAM; GAMMA-SECRETASE INHIBITOR; DECREASES PRODUCTION OF BETA-AMYLOID; TREATMENT FOR ALTZHEIMER'S AND DOWN'S SYNDROME | DUPONT PHARMACEUTICALS COMPANY | 2004-03-30 | — | — | US | disclosed |
| US-20020061874-A1 | Substituted cycloalkyls as inhibitors of a beta protein production | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061874-A1 | Substituted cycloalkyls as inhibitors of a beta protein production | APP, BACE1, APH1A | KMT2A 4356/4885NOTCH1 666/4885RBPJ 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.